Última actualización 12 de septiembre de 2026
Key finding
The primary endpoint is the percentage change in body weight from baseline to Week 76.
The SYNCHRONIZE‐2 trial evaluated the effectiveness of Survodutide for weight reduction in individuals with obesity and Type 2 Diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The SYNCHRONIZE‐2 trial evaluated the effectiveness of Survodutide for weight reduction in individuals with obesity and Type 2 Diabetes.
This research is significant as it addresses the urgent need for effective weight management solutions in individuals with obesity and Type 2 Diabetes, conditions that are associated with numerous health risks. Effective interventions can lead to improved health outcomes and reduced complications related to these diseases.
Effectiveness of Survodutide remains unclear based on current evidence. The study's findings may not be generalizable to all populations. Limited information on long-term effects beyond 76 weeks.
Published in
Publication details and source links for this paper.
Sean W, Carel WLR, Biykem B, et al. SYNCHRONIZE‐2: A Global Phase 3 Trial of Survodutide for Weight Reduction in People with Obesity and Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2025;28(2):1490-1498. doi:10.1111/dom.70263
Survodutide led to a percentage change in body weight of -5% from baseline to Week 76.
69.0% of participants had hypertension, indicating a high prevalence of this condition.
67.6% of participants experienced dyslipidaemia, highlighting the need for effective weight management.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Survodutide and Arteriosclerotic cardiovascular disease prevalence, BMI, Body weight, and 7 more.
This study contributes evidence to
Primary intervention
Survodutide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
10
Evidence pairs
1142
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Survodutide → Arteriosclerotic cardiovascular disease prevalence
Survodutide → Arteriosclerotic cardiovascular disease prevalence
Survodutide → Mean age of participants
Survodutide → Mean age of participants
Survodutide → Prevalence of hypertension among participants
Survodutide → Prevalence of hypertension among participants
Survodutide → Proportion of participants meeting weight goal
Survodutide → Proportion of participants meeting weight goal
Survodutide → Risk of Obstructive Sleep Apnoea (OSA)
Survodutide → Risk of Obstructive Sleep Apnoea (OSA)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Survodutide and Body Weight, Survodutide and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Survodutide
Contributes to Survodutide evidence base.
All studies measuring Dyslipidemia prevalence
Measures Dyslipidemia prevalence as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Survodutide may lower HbA1c.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear effect of Survodutide on body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Survodutide for arteriosclerotic cardiovascular disease prevalence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Arteriosclerotic cardiovascular disease prevalence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear effect of Survodutide on BMI.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
